Teva Pharmaceuticals

@TevaUSA ↗

Deleted No

Hibernated No

Last Checked April 3, 2023

Created

Wed Nov 09 17:03:05 +0000 2022

Likes

Retweets

Source

Twitter for iPhone

View Raw Data

JSON Data

View on Twitter

Likely Available

Teva Pharmaceuticals @TevaUSA

The passage of #BsUFA III showcases forward-thinking goals aimed at bringing biosimilars to market faster, improving patient access, and delivering savings across the system – Teva’s Cory Wohlbach states, live @AccessibleMeds #GRxBiosims https://t.co/e6GSbDpkR6 — PolitiTweet.org

Posted Nov. 9, 2022

Preceded By

Teva Pharmaceuticals @TevaUSA

Cory Wohlbach is back onstage today at #GRxBiosims breaking down the Biosimilar User Fee Act (BsUFA III), recently reauthorized by Congress. Cory is shedding light on FDA’s new regulatory science pilot program aimed at advancing biosimilar products. https://t.co/AGjuOBAWi3 — PolitiTweet.org

Posted Nov. 9, 2022

Followed By

Teva Pharmaceuticals @TevaUSA

Teva’s Janet Vaughn will be on stage soon @GRxBiosims to highlight regulatory barriers and opportunities for improvement within the complex generics space. https://t.co/OtN3p6UHjO — PolitiTweet.org

Posted Nov. 9, 2022